Главная
Study mode:
on
1
Intro
2
Changing Geographic Distribution of IBD
3
Main Susceptibility Genes for Crohn's Disease
4
Microbial Diversity in Crohn's Disease
5
Management of Mild to Moderate UC
6
Estimate of Efficacy of AZA for Treatment Success in UC Patients: Meta-Analysis
7
Infliximab for UC: ACT 1 and ACT 2 Clinical Remission
8
ACT1/2 Trials: Survival Free of Colectomy
9
Cyclosporine vs. Infliximab for Acute Severe UC Treatment Failure, %
10
Management of Crohn's Disease
11
Construct of Biologic Agents Used in Crohn's Disease
12
Induction of Clinical Remission at Week 4 In Crohn's Disease: Certolizumab, Adalimumab, Infliximab
13
Natalizumab (Anti-Alpha 4 Integrin) Therapy for Crohn's Disease
14
Baseline Factors Associated with Time to Surgery: Crohn's, Olmsted County, 1970-2004
15
Advances in IBD Natural History: Predictors of More Severe Disease
16
CT Enterography Healing: Equivalent to Mucosal Healing at Endoscopy?
17
TPMT Activity in 407 New Zealand Patients
18
Meta-Analysis: Association Between 6-TGN Levels and Clinical Remission
19
Effect of Trough Serum Infliximab Concentrations on Clinical Outcome at 52 Weeks
20
What Factors influence the Pharmacokinetics of TNF Antagonists?
21
Active Monitoring of Anti-TNF Levels May Ensure Durability of Response
22
Effect of Concomitant Azathioprine or Methotrexate on Anti-drug Antibodies
Description:
Explore advances in inflammatory bowel disease (IBD) management through this comprehensive grand rounds presentation by Dr. Edward Loftus, Jr. from Mayo Clinic's Gastroenterology/Hepatology department. Delve into the changing geographic distribution of IBD, main susceptibility genes for Crohn's disease, and microbial diversity. Learn about treatment strategies for ulcerative colitis and Crohn's disease, including the efficacy of various medications such as azathioprine, infliximab, and other biologic agents. Examine factors influencing disease progression, surgical outcomes, and the importance of monitoring drug levels and antibodies in TNF antagonist therapy. Gain insights into the latest research on predictors of severe disease, mucosal healing, and pharmacokinetics of IBD treatments.

Advances in Inflammatory Bowel Disease

Mary Greeley Medical Center
Add to list
0:00 / 0:00